2116 POSTER Nab-Paclitaxel weekly or Q3Wks compared to Docetaxel Q3Wks as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

G.Dranitsaris; R.Coleman; W.J.Gradishar

首页> 外文期刊>European Journal of Cancer Supplements >2116 POSTER Nab-Paclitaxel weekly or Q3Wks compared to Docetaxel Q3Wks as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

【24h】

2116 POSTER Nab-Paclitaxel weekly or Q3Wks compared to Docetaxel Q3Wks as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

机译：每周2116次POSTER Nab-紫杉醇或Q3Wks与Docetaxel Q3Wks相比作为转移性乳腺癌患者的一线治疗：一项前瞻性随机试验的经济分析

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements 》 |2007年第4期| 共1页
作者
G.Dranitsaris; R.Coleman; W.J.Gradishar;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. [J] . Dranitsaris G, Coleman R, Gradishar W Breast cancer research and treatment. . 2010 ,第3期

机译：转移性乳腺癌患者每周或每3周与标准多西紫杉醇比较nab-紫杉醇作为一线治疗的前瞻性随机试验的经济分析。
2. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial [J] . George Dranitsaris, Robert Coleman, William Gradishar Breast Cancer Research and Treatment . 2010 ,第3期

机译：转移性乳腺癌患者每周或每3周与标准多西紫杉醇相比nab-紫杉醇作为一线治疗的前瞻性随机试验的经济分析
3. 5066 Nab-paclitaxel weekly or Q3w compared to docetaxel Q3w as first-line therapy in patients with metastatic breast cancer (MBC): an economic analysis of a prospective randomized trial from the perspective of the German health care system [J] . G.Dranitsaris, T.Sch?ning European Journal of Cancer Supplements . 2009 ,第2期

机译：与多西他赛Q3w相比，每周5066纳布紫杉醇或Q3w作为转移性乳腺癌（MBC）患者的一线治疗：从德国医疗体系的角度对一项前瞻性随机试验进行经济分析
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. Supportive Care for Patients with Breast Cancer by Using an Interactive App During Neoadjuvant Chemotherapy: A Randomized Controlled Trial [D] . Fjell, Maria. 2021

机译：通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理：随机对照试验
6. Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial [O] . Denise A. Yardley, Adam Brufsky, Robert E. Coleman, 2016

机译：勘误：‘每周II / III期nab-紫杉醇联合吉西他滨或卡铂与吉西他滨/卡铂作为转移性三阴性乳腺癌患者的一线治疗（tnAcity研究）：一项随机对照试验的研究方案
7. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (vol 16, pg 575, 2015) [O] . Yardley D.A., Brufsky A., Coleman R.E., 2016

机译：II / III期每周nab-紫杉醇加吉西他滨或卡铂与吉西他滨/卡铂作为转移性三阴性乳腺癌患者的一线治疗（tnacity研究）：随机对照试验的研究方案（第16卷，第575页， 2015年）

2116 POSTER Nab-Paclitaxel weekly or Q3Wks compared to Docetaxel Q3Wks as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

著录项

相似文献

相关主题

期刊订阅